| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/10/2003 | WO2002055152A3 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| 04/10/2003 | WO2002050122A3 Means for the diagnosis and therapy of ctcl |
| 04/10/2003 | WO2002049629A3 Methods for reducing chronic stress in mammals |
| 04/10/2003 | WO2002046406A3 Human transporter proteins, nucleic acid molecules encoding them,and uses thereof |
| 04/10/2003 | WO2002040666A3 Fat regulated genes, uses thereof, and compounds for modulating same |
| 04/10/2003 | WO2002036135A3 Compositions for antitumour treatment containing ecteinascidin 743 |
| 04/10/2003 | WO2002008396A3 Human proteases |
| 04/10/2003 | US20030070184 Ligands for discoidin domain receptor tyrosine kinases and complexes thereof |
| 04/10/2003 | US20030069445 Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide |
| 04/10/2003 | US20030069428 Pharmaceutically active isoindoline derivatives |
| 04/10/2003 | US20030069424 Indolylmaleimide derivatives |
| 04/10/2003 | US20030069316 Use of comt inhibitors as analgesics |
| 04/10/2003 | US20030069315 New use for 1,3-propanediol derivatives |
| 04/10/2003 | US20030069301 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| 04/10/2003 | US20030069297 4-aryl substituted indolinones |
| 04/10/2003 | US20030069296 Central nervous system disorders |
| 04/10/2003 | US20030069286 Vision defects |
| 04/10/2003 | US20030069284 Anticancer agent |
| 04/10/2003 | US20030069277 Anticancer agents |
| 04/10/2003 | US20030069272 Prevent joint stiffness; adjust concentration of synovial fluid |
| 04/10/2003 | US20030069270 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxImic acid derivative |
| 04/10/2003 | US20030069266 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 04/10/2003 | US20030069255 Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| 04/10/2003 | US20030069253 Compositions and methods for treating otic, ophthalmic and nasal infections |
| 04/10/2003 | US20030069252 Viricides; antiinflammatory agents |
| 04/10/2003 | US20030069246 Central nervous system disorders; psychological disorders; cardiovascular disorders |
| 04/10/2003 | US20030069245 Aids therapy |
| 04/10/2003 | US20030069238 Anticancer agents; immunology diseases; antiallergens; antiinflammatory agents |
| 04/10/2003 | US20030069221 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 04/10/2003 | US20030069213 Oral preparation |
| 04/10/2003 | US20030069201 Methods of using BCL-2 for the therapeutic treatment and prevention of diseases |
| 04/10/2003 | US20030069200 Use of glucosylceramide synthesis inhibitors in brain cancertherapy |
| 04/10/2003 | US20030069199 Treatment methods based on microcompetition for a limiting GABP complex |
| 04/10/2003 | US20030069191 Pantethinesulphonic acid and/or a salt thereof as a free-radical scavenger |
| 04/10/2003 | US20030069189 Administering an NF-kappa B activation inhibitor that is a proteasome inhibitor, ubiquitin pathway inhibitor, agent that interferes with activation of NF-kappa B via the ubiquitin proteasome pathway |
| 04/10/2003 | US20030069169 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders |
| 04/10/2003 | US20030068817 Tubularized tissue; for use in the treatment of hypoxia, vascular necrosis, foot ulcer diabetes, athersclerosis, stroke, wounds and bone fractures |
| 04/10/2003 | US20030068678 WISP polypeptides and nucleic acids encoding same |
| 04/10/2003 | US20030068640 Diagnosing vision defects in mammals; obtain tissue sample, extract nucleotide sequences, detect mutaion in tigr allele, presence of mutation indicates vision defects |
| 04/10/2003 | US20030068616 Evaluating efficiency of drug treatment; obtain cell, transform cell, incubate with modulator, monitor protein activity, adjustment in protein activity indicates modulator |
| 04/10/2003 | US20030068391 Combination of an antioxidant, an antiinflammatory agent, circulatory enhancement agent, vasodilator, nerve growth regeneration agent, gycemic conrol agent, sorbitol inhibitor, lipid reduction agent, pancreatic stem cell support agent |
| 04/10/2003 | US20030068387 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
| 04/10/2003 | US20030068366 Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| 04/10/2003 | US20030068364 Pro-liposomal encapsulated preparations (iv) |
| 04/10/2003 | US20030068359 Poultry and livestock feed additive |
| 04/10/2003 | US20030068351 >/= 1% zinc oxide, a fungicide, a batericide, >/= 5% water-absorbing macromolecular material dispersed in a water immiscible vehicle; treating skin that is exposed to excessive amounts of moisture |
| 04/10/2003 | US20030068343 Phytosphingosine, an antioxidant, an antibacterial of at least hinokitiol and a salicylate, a polysaccharide and gorgornian extract for an anti-irittating effect on skin treated with a retinoid |
| 04/10/2003 | US20030068302 Optimal compositions and methods thereof for treating HCV infections |
| 04/10/2003 | US20030068280 Treatment of respiratory diseases |
| 04/10/2003 | US20030068278 Administering fine powder of active material; measured aerosol |
| 04/10/2003 | US20030068276 Dosage forms |
| 04/10/2003 | US20030066525 Pressurised metered dose inhalers (MDI) |
| 04/10/2003 | US20030066524 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage |
| 04/10/2003 | CA2462802A1 Nutrient medium for maintaining neural cells in injured nervous system |
| 04/10/2003 | CA2462795A1 Secreted proteins |
| 04/10/2003 | CA2462647A1 6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | CA2462602A1 Double stranded rna as an adjuvant in vaccine compositions |
| 04/10/2003 | CA2462601A1 Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | CA2462443A1 Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease |
| 04/10/2003 | CA2462425A1 Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
| 04/10/2003 | CA2462424A1 A novel g protein-coupled receptor, gave 10 |
| 04/10/2003 | CA2462305A1 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/10/2003 | CA2461877A1 Method of treatment using ligand-immunogen conjugates |
| 04/10/2003 | CA2461715A1 Proliferation and differentiation of stem cells using extracellular matrix and other molecules |
| 04/10/2003 | CA2461606A1 Nonhuman mammal model of autoimmune disease having ox40l gene transferred thereinto |
| 04/10/2003 | CA2461586A1 Compounds for the reduction of excessive food intake |
| 04/10/2003 | CA2461197A1 Inhibition of exoproteins using isoprenoids |
| 04/10/2003 | CA2460916A1 Methods and compositions for modulating interleukin-21 receptor activity |
| 04/10/2003 | CA2460261A1 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer |
| 04/10/2003 | CA2460257A1 Methods for diagnosing and treating heart disease |
| 04/10/2003 | CA2458343A1 Pharmaceutical combinations of pde-v inhibitors and other agents |
| 04/10/2003 | CA2438330A1 A method for the early detection of cancer |
| 04/09/2003 | EP1300468A2 TRNA synthetase |
| 04/09/2003 | EP1300146A1 Pharmaceutical composition for the treatment of animal mammary tumors |
| 04/09/2003 | EP1300138A2 Agents effective against hyperreactive and hypoactive deficient skin conditions as well as manifest dermatitis |
| 04/09/2003 | EP1299546A2 Aminoacyl trna synthetases |
| 04/09/2003 | EP1299545A2 Drug metabolizing enzymes |
| 04/09/2003 | EP1299538A2 Secreted proteins |
| 04/09/2003 | EP1299534A2 Grf2-binding proteins and applications thereof |
| 04/09/2003 | EP1299522A2 Alteration of cell membrane |
| 04/09/2003 | EP1299415A1 Chemokine receptor modulators, production and use |
| 04/09/2003 | EP1299412A2 Protein modification and maintenance molecules |
| 04/09/2003 | EP1299411A1 Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| 04/09/2003 | EP1299385A2 Fused cyclic modulators of nuclear hormone receptor function |
| 04/09/2003 | EP1299382A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives |
| 04/09/2003 | EP1299358A2 Pyridoxine and pyridoxal analogues: cardiovascular therapeutics |
| 04/09/2003 | EP1299348A1 Compounds and compositions for delivering active agents |
| 04/09/2003 | EP1299134A1 The use of honey in wound dressings |
| 04/09/2003 | EP1299123A2 Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| 04/09/2003 | EP1299122A2 Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
| 04/09/2003 | EP1299121A2 Thromboxane receptor antagonist containing formulations for potentiating organic nitrates having vasodilating activity |
| 04/09/2003 | EP1299119A2 Immunosuppressive compositions comprising an immunophilin-binding compound and a ginkgolide compound |
| 04/09/2003 | EP1299114A1 Diclofenac pharmaceutical composition based on vitamin-e, papain and hyaluronidase |
| 04/09/2003 | EP1299112A2 Compositions for treating eye discomfort, containing herbals and/or nutritional supplements and/or minerals and/or vitamins |
| 04/09/2003 | EP1299110A2 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites |
| 04/09/2003 | EP1299104A1 Tamper-resistant oral opioid agonist formulations |
| 04/09/2003 | EP1299100A1 Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist |
| 04/09/2003 | EP1299099A2 Novel use of (r)-(-)-2- 5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts |
| 04/09/2003 | EP1299094A2 Selective androgen receptor modulators and methods for their identification, design and use |
| 04/09/2003 | EP1299093A2 Combinations of bisphosphonates, estrogenic agents and optionally estrogens |